Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04471974
Title ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors Rahul Aggarwal
Indications

prostate adenocarcinoma

prostate small cell carcinoma

Therapies

Enzalutamide + Pembrolizumab + ZEN-3694

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST